Last reviewed · How we verify
GT160-246
At a glance
| Generic name | GT160-246 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea (PHASE3)
- A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea (PHASE2)
- A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea (PHASE3)
- A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea (PHASE2)
- A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GT160-246 CI brief — competitive landscape report
- GT160-246 updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI